Price T Rowe Associates Inc Myriad Genetics Inc Transaction History
Price T Rowe Associates Inc
- $935 Billion
- Q3 2025
A detailed history of Price T Rowe Associates Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 60,274 shares of MYGN stock, worth $404,438. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,274
Previous 55,176
9.24%
Holding current value
$404,438
Previous $293,000
48.81%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding MYGN
# of Institutions
238Shares Held
92.1MCall Options Held
86.1KPut Options Held
18.9K-
Black Rock Inc. New York, NY15.2MShares$102 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.88MShares$52.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.98MShares$33.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.75MShares$31.9 Million0.02% of portfolio
-
Glenview Capital Management, LLC New York, NY4.59MShares$30.8 Million0.75% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $541M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...